LONDON — An investigation is under way after a newborn baby was given 10 times the normal dose of a tuberculosis vaccine at a hospital in North Lincolnshire, England.

National Institute of Allergy and Infectious Diseases

A vaccine could cut tuberculosis cases among HIV-positive Africans by almost two-fifths, a U.S. study suggests.

TB

Public health officials are concerned about the implications of the first U.S. case of extremely drug-resistant tuberculosis, diagnosed in a 19-year-old Peruvian who is visiting here to study English, Homeland Security Today reported Dec. 29.

TB

The number of people developing tuberculosis continues to increase despite earlier signs of stabilizing, according to a report released Dec. 2 by the United Kingdom’s Health Protection Agency.

TB

National Health Service efforts to tackle tuberculosis in England are improving, but worryingly nearly 18 percent TB hot spot areas, and 60 percent of all areas, still don't have a strategy in place to tackle the disease.

SAN DIEGO — Researchers from the La Jolla Institute for Allergy & Immunology will take aim at several of the world's most dangerous infectious diseases — tuberculosis, malaria and dengue virus.

TB

Health experts will in the coming weeks converge in Mayuge and Iganga districts for a clinical trial, to test the world's first experimental tuberculosis vaccine in nearly a century, allAfrica.com reported Dec. 9.

Tuberculosis

CANCUN, Mexico — Health experts called for more research funding to develop better diagnostic tests, vaccines and drugs for tuberculosis, which killed 1.8 million people around the world last year.

Dr. Anthony Fauci

Dr. Anthony Fauci wrote this commentary, posted Nov. 17, for msnbc.com. He is director of the National Institute of Allergy and Infectious Diseases in Bethesda, Md.

Fuad El-Hibri

ROCKVILLE, Md. — Emergent BioSolutions Inc. announced that it has completed the acquisition of a 55,000-square-foot manufacturing facility from MdBio Foundation and the land on which the facility stands from the city of Baltimore.

With all the attention on H1N1 and the seasonal flu, it might be easy to forget about other infectious diseases.

The Oxford-Emergent Tuberculosis Consortium Ltd. has signed an agreement with Vivalis to evaluate large-scale commercial production capabilities for MVA85A, the consortium’s new TB vaccine candidate.

Tuberculosis

OXFORD, United Kingdom; ROCKVILLE, Md.; and NANTES, France — The Oxford-Emergent Tuberculosis Consortium Ltd., announced the signing of a commercial license agreement with Vivalis to evaluate large-scale commercial production capabilities for MVA85A.

Fuad El-Hibri

OXFORD, United Kingdom; ROCKVILLE, Md.; and BERLIN — The Oxford-Emergent Tuberculosis Consortium Ltd. announced the signing of a commercial license agreement with ProBioGen, to evaluate large-scale commercial production capabilities for MVA85A.

TB

The Aeras Global TB Vaccine Foundation, the Oxford-Emergent Tuberculosis Consortium Ltd., Isis Innovation Ltd., the Wellcome Trust and the University of Cape Town announce the start of a Phase IIb proof-of-concept clinical trial of a new TB vaccine.

TB

The University of Oxford and Emergent BioSolutions Inc. announced July 23, 2008, that they have formed the Oxford-Emergent Tuberculosis Consortium Ltd. to further develop MVA85A, a vaccine candidate for the prevention of tuberculosis.